

## 1 Title Page

2 **Title:** Two doses of the mRNA BNT162b2 vaccine reduce severe outcomes, viral load and secondary  
3 attack rate: evidence from a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, January-  
4 March 2021

5 **Authors:** Emily Dorothee Meyer<sup>\*1,2,3</sup>, Mirco Sandfort<sup>1,2,3</sup>, Jennifer Bender<sup>3,4,5</sup>, Dorothea Matysiak-  
6 Klose<sup>6</sup>, Achim Dörre<sup>1</sup>, Gerhard Bojara<sup>7</sup>, Konrad Beyrer<sup>8</sup>, Wiebke Hellenbrand<sup>6</sup>

### 7 Affiliations

8 1. Department of Infectious Disease Epidemiology, Postgraduate Training for Applied Epidemiology  
9 (PAE), Robert Koch Institute, Berlin, Germany

10 2. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease  
11 Prevention and Control (ECDC), Stockholm, Sweden

12 3. These authors contributed equally to this article and share first authorship

13 4. Department of Infectious Diseases, Nosocomial Pathogens and Antibiotic Resistances Unit, Robert  
14 Koch Institute, Berlin, Germany

15 5. European Programme for Public Health Microbiology Training (EUPHEM), European Centre for  
16 Disease Prevention and Control (ECDC), Stockholm, Sweden

17 6. Department of Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Berlin,  
18 Germany

19 7. Local Public Health Authority Osnabrück

20 8. Department of Infectious Diseases, Public Health Agency of Lower Saxony

21 **\*Corresponding author:** Emily Dorothee Meyer

22 **Corresponding author email:** [meyere@rki.de](mailto:meyere@rki.de)

### 23 Abstract

24 A SARS-CoV-2 Alpha outbreak was detected in a nursing home after residents and staff had  
25 completed vaccination with BNT162b. In a retrospective cohort study, we estimated an age-  
26 adjusted vaccine effectiveness of 88% [95% confidence interval (95%CI) 41-98%] against  
27 hospitalization/death. Ct values at diagnosis were higher with longer intervals since the  
28 second vaccination [ $>21$  vs.  $\leq 21$  days: 4.82 cycles, 95%CI: 0.06-9.58]. Secondary attack rates  
29 were 67% lower in households of vaccinated [2/9 (22.2%)] than unvaccinated infected staff  
30 [12/18 (66.7%);  $p=0.046$ ]. Vaccination reduced the risk of severe outcomes, Ct values and  
31 transmission, but not fully. Non-pharmaceutical interventions remain important for vaccinated  
32 individuals.

33

## 34 Text

### 35 Background

36 While COVID-19 case-fatality was <0.1% in under-50-year-olds [1], it was 13% in outbreaks of SARS-  
37 CoV-2 in nursing homes from January 2020 to February 2021 in Germany [2]. Hence, nursing homes  
38 were prioritized for COVID-19 vaccination which began in Germany in December 2020 [3]. We report  
39 on a SARS-CoV-2 Alpha (B.1.1.7) outbreak among residents and staff of a nursing home in Germany,  
40 of whom some were vaccinated with two doses of BNT162b. This study describes the epidemiology  
41 of the outbreak, the undertaken control measures and the vaccine effectiveness (VE) against SARS-  
42 CoV-2 Alpha infections, disease and severe outcomes (hospitalization or death) and the vaccine  
43 effects on viral load and secondary transmission.

### 44 Study design

45 Cases were defined as residents (either permanent or day-care) or staff who had a positive SARS-  
46 CoV-2-PCR between early January 2021 (symptom onset of first case denoted as day 0) and mid-  
47 March 2021 (2 weeks after diagnosis of the last case, day 74). In a retrospective cohort study, we  
48 included all residents and staff who attended the nursing home during the same time period. We  
49 compared attack rates (AR) with Chi-squared or Fisher's exact tests. We estimated vaccine  
50 effectiveness (VE) as  $VE=1-RR$ , where RR denotes the relative risk for the respective outcome in  
51 vaccinated vs. unvaccinated individuals, calculated by Poisson regression. Considered outcomes were  
52 SARS-CoV-2 infection, symptomatic infection and severe courses (defined as hospitalization or death  
53 from COVID-19). Using linear regression, we analyzed the effect of the time interval between the  
54 second vaccine dose and viral load at diagnosis (using Ct value for the ORF1AB gene at the first  
55 positive PCR as a proxy). Unvaccinated cases were assigned an interval of 0 days. We assessed  
56 secondary attack rates (SAR) among household members of SARS-CoV-2-positive staff, who were  
57 tested twice during their quarantine. One household outside the administrative district was excluded

58 because data was unavailable. Secondary cases were defined as SARS-CoV-2 PCR-positive household  
59 members diagnosed 1-14 days after the diagnosis of the corresponding staff index case.

## 60 Ethical statement

61 This outbreak investigation was conducted in accordance to paragraph 4 of the German Protection  
62 against Infection Act. Therefore, this investigation was exempt from additional institutional review.

## 63 Study setting

64 The nursing home comprised one day-care and seven permanent care wards with 128 members of  
65 staff, 100 residents in permanent care and 24 persons in day-care. Ninety-five/124 (77%) residents  
66 and 72/128 (56%) staff members were vaccinated with BNT162b in early and late January 2021, with  
67 an inter-dose interval of three weeks. Median age was 49 years among staff (inter-quartile range  
68 (Q25-Q75): 32-58) and 87 years among residents (Q25-Q75: 83-92). Among residents, 97/124 (77%)  
69 and among staff, 113/128 (88%) were female.

## 70 Measures in place before the outbreak

71 All staff had to conduct daily rapid antigen detection tests (RADT). Residents were tested related to  
72 incidences, e.g. when becoming symptomatic. All visitors of the nursing homes could only enter with  
73 a negative RADT of the same day. Staff and visitors had to wear FFP2 standard masks inside the  
74 nursing home. Staff was assigned in teams to designated wards and rotation between wards was  
75 minimized. However, this was not possible for night shifts and social workers.

## 76 The epidemiology of the outbreak

77 After detecting the first SARS-CoV-2 infection in a permanent care resident in early February 2021  
78 (day 30) and previous, sporadic cases among four staff since early January 2021 (day 0), an outbreak  
79 investigation was initiated. Between early January 2021 (day 0) and 14 days after the detection of the  
80 last case in mid-March 2021 (day 74), 50 SARS-CoV-2 cases were detected, of which 35 were  
81 symptomatic (70%; 16/35 (46%) vaccinated). Four residents (1/4 (25%) vaccinated) were hospitalized

82 and five died (2/5 (40%) vaccinated) from or with COVID-19. The crude AR among residents (AR=27%,  
83 34/124) was higher than among staff (AR=12%, 16/128,  $p<0.01$ ). Typing of PCR samples for variants  
84 of concern detected variant Alpha in 27/28 samples.

### 85 The course of the outbreak

86 A kitchen staff, working in a kitchen serving all sections, developed symptoms on day 0, worked for  
87 two more days prior to isolation with no reported contacts to other care sections. Between day 8 and  
88 day 23, mainly the day-care was affected with nine detected cases (eight residents and one member  
89 of staff) and was therefore closed. In the stationary care, two members of staff developed symptoms  
90 on day 28 and a resident was RADT-positive on day 30. Subsequently, the outbreak spread in the  
91 permanent care wards, see Figure 1 and 2.

### 92 Potential sources of the outbreak

93 All members of the vaccination team were tested negative with daily RADT and with weekly PCR.  
94 Therefore, it seems unlikely that the vaccination team was the source of the outbreak. Initially, no  
95 links between the day-care and the stationary care were reported. However, the contact tracing  
96 information revealed that an external health-care worker (ID-5160, see Figure 3) visited a highly  
97 infectious case (ID-2640, Ct value 11) from the day-care on day 10 and a person from the permanent  
98 care (ID-870) on day 12 (who tested positive later), suggesting that they visited ID-870 within the  
99 infectious period. ID-5160 was tested positive with an RADT on day 13. Potentially, the ID-5160  
100 represents a link between these two sections. However, no sequencing data was available to further  
101 delineate possible transmission chains. The other 165 visitors of the nursing home did not have  
102 timely relevant SARS-CoV-2 infections and were therefore excluded as potential sources of  
103 infections.

### 104 Outbreak management

105 On day 32, 4 days after the first member of staff of the stationary care was symptomatic, regular PCR  
106 serial testing was implemented for all residents and staff every 5 days until two consecutive PCR

107 serial tests had negative results only. All symptomatic or PCR-positive residents were isolated as a  
108 cohort on a designated ward. Non-cases could move within their ward but contacts between wards  
109 were minimized. Close contacts were quarantined in their rooms. Case isolation ended once cases  
110 were asymptomatic and were PCR-negative at the earliest after 14 days. No visitors were allowed  
111 between day 31 and day 74.

## 112 Vaccine effectiveness

113 Among 29 vaccinated cases, the date of diagnosis (defined as the earlier date of either symptom-  
114 onset or sampling of a positive test) was 7-11 days after the second vaccine in 14 cases (48%, all  
115 residents), while 15 (52%) were diagnosed 20 or more days post vaccination. SARS-CoV-2 infections  
116 were diagnosed less frequently among vaccinated than unvaccinated residents (Table 1,  $p=0.46$ ) and  
117 staff (Table 1,  $p=0.06$ ). Age-adjusted VE  $\geq 7$  days after two doses of BNT162b was 45% (0-69%,  
118  $p=0.048$ ) against infection. Among residents and staff, vaccinated cases were less symptomatic than  
119 unvaccinated cases (Table 1, residents:  $p=0.04$ , staff:  $p<0.01$ ). Age-adjusted VE was 68% (36-84%;  
120  $p<0.01$ ) against disease. Of 50 cases, four were hospitalized (1/4 (25%) vaccinated) and five (2/5  
121 (40%) vaccinated) died (all residents). Age-adjusted VE  $\geq 7$  days after completed vaccination was 88%  
122 (37-98%;  $p=0.01$ ) against severe outcomes.

123 Age confounded the association between vaccination status and infection, disease and severe  
124 outcomes, changing effect estimates by 21% (from 0.70 to 0.55), 20% (from 0.40 to 0.32) and 50%  
125 (from 0.24 to 0.12), respectively (Table 2). Gender was not associated with risks for infection ( $p=0.64$ )  
126 or disease ( $p=0.69$ ), but women exhibited a lower risk for severe outcomes ( $p=0.07$ , Table 2),  
127 however not after adjusting for age and vaccination status [RR=0.34, 95%CI: 0.06-1.85,  $p=0.20$ ].

128 Among symptomatic cases, no association of the time interval between the second vaccine dose and  
129 diagnosis with the risk for severe outcomes was observed (time in days: IRR=0.93, 95%CI: 0.76 – 1.06,  
130  $p=0.34$ ; 7-14 days vs.  $>14$  days: IRR=0.78, 95%CI:0.10-15.81,  $p=0.83$ ), adjusted for age.

## 131 Vaccination reduced the viral load

132 Ct values at diagnosis were on average 3.04 cycles (Table 3,  $p=0.28$ ) higher among vaccinated than  
133 unvaccinated cases. The Ct value increased with time since the second vaccine dose (Table 3 and  
134 Figure 3). Age ( $p=0.79$ ) and sex ( $p=0.61$ ) was not associated with the Ct value (Table 3).

## 135 Vaccination reduced secondary transmission in households

136 We analyzed 14 households of SARS-CoV-2-positive staff (five vaccinated, nine unvaccinated). We  
137 found two secondary cases in 1/5 (20%) households of vaccinated staff (index staff case was  
138 diagnosed 25 days after the second vaccination) and 12 secondary cases in 5/9 (56%) households of  
139 infected, unvaccinated staff. For calculating the adjusted SAR, we excluded household members with  
140 a PCR-confirmed SARS-CoV-2 infection <6 months prior or who quarantined separately from infected  
141 staff. Household members with a vaccinated index case had a lower SAR [2/9 (22%)] than household  
142 members of unvaccinated SARS-CoV-2-positive staff ( $p=0.046$ , Fisher's exact test, Table 4).

## 143 Discussion

144 In our study, the age-adjusted VE of two doses of BNT162b was moderate against infection and  
145 disease and high against severe COVID-19. Our VE estimates are lower than in a population-based  
146 cohort study conducted in Israel [4] that reported a VE of 96% against hospitalization and 93%  
147 against death. This can be explained by a higher potential for repeated contacts with infected cases  
148 and a higher median age in this outbreak setting. Furthermore, half of the vaccinated cases were  
149 diagnosed within 7-11 days after the second vaccination; thus, infection occurred prior to attaining  
150 full immunity. However, we did not observe higher effectiveness among cases with a longer interval  
151 between the second vaccine and diagnosis, in line with findings from the UK [5]. Our analysis is  
152 limited by the small sample size and inability to control for risk factors such as underlying chronic  
153 diseases and compliance with protective measures. The individual risk of infection possibly changed  
154 over time with the implementation of non-pharmaceutical control measures, such as separating  
155 cases from non-cases, thereby potentially biasing the VE results of our study.

156 Our VE against infection was lower than in previous studies from similar settings [4], [6], [7]. Since  
157 this cohort was PCR-tested every 5-6 days throughout the outbreak, we believe that the risk for  
158 missing asymptomatic cases was minimal while in other studies under-ascertainment of  
159 asymptomatic infection may have occurred.

160 We found a significantly lower Ct value among vaccinated cases  $\geq 21$  days after the second vaccine (6  
161 weeks after the first) than among non-vaccinated cases. One study assessing a similar study  
162 population [8] found lower viral loads already four weeks after the first vaccination. However, the  
163 authors pooled different Ct values from all available PCR-positive results, which may have impacted  
164 the inter-assay comparability [9], especially considering N-gene dropouts with the Alpha variant [10].

165 Our results suggest that while transmission was reduced, close contacts of vaccinated persons with  
166 break-through SARS-CoV-2 infections remained at risk for infection, as shown in previous studies for  
167 household members of healthcare workers vaccinated with BNT162b2 [11]. As no samples could be  
168 sequenced, our results are limited by the inability to show that primary and secondary cases had  
169 identical viral strains. Still, these results have strong implications for policy makers because they  
170 emphasize that adhering to non-pharmaceutical interventions is still very important for vaccinated  
171 people.

172 We believe that the regular PCR serial testing, isolating cases on a designated ward and quarantining  
173 close contacts of cases in their rooms contributed to the successful outbreak control. It is possible  
174 that the outbreak on the day-care and the stationary ward were linked via a visiting health-care  
175 worker. However, typing revealed that at least two different strains were present in this outbreak,  
176 suggesting two introductory events of SARS-CoV-2 at minimum.

## 177 **Conclusions**

178 Two doses of BNT162b significantly reduced the risk for SARS-CoV-2 infections, symptomatic  
179 infections, severe outcomes, viral load and secondary transmission, even within 14 days after the  
180 second dose. However, the incomplete protection emphasizes that adhering to non-pharmaceutical

181 interventions remains important after completed vaccination. When reconsidering non-  
182 pharmaceutical measures for fully vaccinated people, policy makers need to be aware that the risk  
183 reduction for vaccination people regarding the risk for infection, severe outcomes and transmission is  
184 incomplete. Regular PCR serial testing and isolation of cases on a designated ward contributed to the  
185 outbreak control.

## 186 Acknowledgement

187 The authors are grateful for the work and the commitment of all public health staff throughout the  
188 pandemic. The authors would like to specifically thank the Local Public Health Authority, Osnabrück,  
189 the Department of Infectious Diseases of the Public Health Agency of Lower Saxony, Hannover,  
190 Germany and the staff of the affected nursing home for their cooperation in the investigation. Emily  
191 Meyer, Mirco Sandfort and Jennifer Bender would like to thank their frontline coordinators Sybille  
192 Rehmet, Katharina Alpers and Loredana Ingrassio for their continuous support.

## 193 Financial support

194 EM and MS are fellows of the German postgraduate training for applied epidemiology (PAE). JB is a  
195 fellow of the ECDC Fellowship Programme, supported financially by the European Centre for Disease  
196 Prevention and Control (ECDC). This research received no specific grant from any funding agency,  
197 commercial or not-for-profit sectors.

## 198 Disclaimers

199 No conflict of interest reported. JB is a fellow of the ECDC Fellowship Programme. The views and  
200 opinions expressed herein do not state or reflect those of the ECDC. The ECDC is not responsible for  
201 the data and information collection and analysis and cannot be held liable for conclusions or opinions  
202 drawn.



## 203 Data availability statement

204 Aggregated data from a limited version of the German notification system database can be retrieved  
205 via SurvStat@RKI 2.0 <https://survstat.rki.de/>. Detailed data are confidential and protected by  
206 German law and are available from the corresponding author upon reasonable request.

## 207 References

- 208 [1] Robert-Koch-Institut, “RKI - Infektionskrankheiten A-Z - Epidemiologischer Steckbrief zu SARS-  
209 CoV-2 und COVID-19”, 2021.  
210 [https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\\_Coronavirus/Steckbrief.html;jsessionid=](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html;jsessionid=8626D400296162979EAA91A303BC1216.internet072?nn=2386228)  
211 [8626D400296162979EAA91A303BC1216.internet072?nn=2386228](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html;jsessionid=8626D400296162979EAA91A303BC1216.internet072?nn=2386228) (accessed Jan. 11, 2021).
- 212 [2] B. Schweickert *et al.*, “COVID-19-Ausbrüche in deutschen Alten- und Pflegeheimen  
213 Hintergrund,” *Epid Bull*, no. 18, pp. 3–29, 2021.
- 214 [3] S. Vygen-Bonnet *et al.*, “Beschluss der STIKO zur 1. Aktualisierung der COVID-19-  
215 Impfpfempfehlung und die dazugehörige wissenschaftliche Begründung - STIKO-Empfehlung zur  
216 COVID-19-Impfung ” 2021. [Online]. Available:  
217 [https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02\\_21.pdf](https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02_21.pdf).
- 218 [4] E. J. Haas *et al.*, “Nationwide vaccination campaign with BNT162b2 in Israel demonstrates  
219 high vaccine effectiveness and marked 3 declines in incidence of SARS-CoV-2 infections and  
220 COVID-19 cases, hospitalizations, and deaths,” [Online]. Available:  
221 <https://ssrn.com/abstract=3811387>.
- 222 [5] B. JL *et al.*, “Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and  
223 ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in  
224 older adults in England,” Mar. 2021, doi: 10.1101/2021.03.01.21252652.
- 225 [6] M. S *et al.*, “Direct and indirect effectiveness of mRNA vaccination against SARS-CoV-2  
226 infection in long-term care facilities in Spain,” Apr. 2021, doi: 10.1101/2021.04.08.21255055.

- 227 [7] I. Rask Moustsen-Helms *et al.*, “Vaccine effectiveness after 1st and 2nd dose of the BNT162b2  
228 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers-a Danish  
229 cohort study Corresponding Author,” Mar. 2021, doi: 10.1101/2021.03.08.21252200.
- 230 [8] M. Shrotri *et al.*, “Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2  
231 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study),” doi:  
232 10.1101/2021.03.26.21254391.
- 233 [9] C. Buchta *et al.*, “Variability of cycle threshold values in an external quality assessment  
234 scheme for detection of the SARS-CoV-2 virus genome by RT-PCR,” *Clin. Chem. Lab. Med.*, vol.  
235 59, no. 5, pp. 987–994, Apr. 2021, doi: 10.1515/cclm-2020-1602.
- 236 [10] P. Wollschlaeger *et al.*, “SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for  
237 the presence of B.1.1.7 lineage in a commercial multiplex PCR assay,” *Clin. Microbiol. Infect.*,  
238 May 2021, doi: 10.1016/j.cmi.2021.05.025.
- 239 [11] R. J. Harris, J. A. Hall, A. Zaidi, N. J. Andrews, J. Kevin Dunbar, and G. Dabrera, “Impact of  
240 vaccination on household transmission of SARS-COV-2 in England”, 2021. [Online] Available:  
241 <https://pubmed.ncbi.nlm.nih.gov/34161702/>, doi: 10.1056/NEJMc2107717

242

243

244 **Tables**

245

246 *Table 1: Outcomes of a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021, stratified by*  
 247 *vaccination status among residents, staff and all.*

	Vaccination		Case		Symptomatic		Hospitalization		Death		
		n	%	n	AR	n	% of cases	n	% of cases	n	% of cases
Residents	No	29		10	34%	8	80%	3	30%	3	30%
	Yes	95	77%	24	25%	13	54%	1	4%	2	8%
Staff	No	56		11	20%	11	100%	0	0%	0	0%
	Yes	72	56%	5	7%	3	60%	0	0%	0	0%
Total	No	85		21	25%	19	90%	3	14%	3	14%
	Yes	167	66%	29	17%	16	55%	1	3%	2	7%

248 Attack rate (AR) with the strata size as denominator. Symptomatic cases, hospitalization and deaths  
 249 with respective number of cases as denominator.

250

251 **Table 2. Risk for SARS-CoV-2 infection, risk for symptomatic infection and risk for severe outcome (hospitalization or**  
 252 **death) during a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021.**

		<b>Risk for infection</b>			
		Univariate		Multivariable	
Variable		RR (95%CI)	p-value	RR (95%CI)	p-value
Age	Years	1.02 (1.00-1.03)	0.01	1.02 (1.01-1.03)	<0.01
Sex	Female	0.85 (0.44-1.79)	0.64		
	Male	<i>Ref</i>			
Vaccination	Yes	0.70 (0.40-1.25)	0.22	0.55 (0.31-1.00)	0.048
	No	<i>Ref</i>			
		<b>Risk for symptomatic infection</b>			
		Univariate		Multivariable	
Variable		RR (95%CI)	p-value	RR (95%CI)	p-value
Age	Years	1.01 (0.99-1.02)	0.24	1.02 (1.00-1.03)	0.04
Sex	Female	0.84 (0.39-2.10)	0.69		
	Male	<i>Ref</i>			
Vaccination	Yes	0.40 (0.20-0.78)	<0.01	0.32 (0.16-0.64)	<0.01
	No	<i>Ref</i>			
		<b>Risk for severe outcome</b>			
		Univariate		Multivariable	
Variable		RR (95%CI)	p-value	RR (95%CI)	p-value
Age	Years	1.11 (1.03-1.26)	<0.01	1.12 (1.04-1.27)	<0.001
Sex	Female	0.21 (0.04-1.14)	0.07		
	Male	<i>Ref</i>			
Vaccination	Yes	0.24 (0.03-1.23)	0.09	0.12 (0.02-0.59)	0.01
	No	<i>Ref</i>			

253 Estimates of risk ratios (RR) and 95% confidence intervals (CI) were calculated with uni- and  
 254 multivariable Poisson regression models. P-values from log-likelihood ratio test. Reference levels of  
 255 categorical variables are indicated by “Ref”. Variables were included in a multivariate model if the  
 256 log-likelihood ratio test resulted in  $p \leq 0.05$ .

257  
258

*Table 3: Associations with the Ct value of the PCR at diagnosis in a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021.*

Variable		Coefficient	95%CI	p-value
<b>Age</b>	$\Delta$ years	-0.02	-0.15 – 0.12	0.80
<b>Sex</b>	Female	1.53	-4.81 – 7.87	0.63
	Male	Ref		
<b>Symptoms</b>	No	6.32	1.89 – 10.75	<b>&lt;0.01</b>
	Yes	Ref		
<b>Vaccination</b>	Yes	3.04	-2.86 - 8.93	0.30
	No	Ref		
<b>Time interval between second vaccine and diagnosis</b>	$\Delta$ days	0.23	0.01 - 0.45	<b>0.04</b>
	> 14 days	3.53	-1.15 - 8.22	<b>0.13</b>
	$\leq$ 14 days	Ref		
	> 21 days	4.82	0.06 – 9.58	<b>0.047</b>
	$\leq$ 21 days	Ref		

259 The results were calculated with univariate linear regression models.  $\Delta$ : indicates a numerical  
260 variable. 95%CI: 95% confidence interval; P-values are based on Wald tests.

261

262 *Table 4: Secondary SARS-CoV-2 cases and secondary attack rate (SAR) in households of SARS-CoV2-positive staff,*  
 263 *stratified by vaccination status, during a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021.*

Vaccination status of index staff case	Household members					Crude Analysis		Adjusted Analysis	
	Total	Infected	Prior	Separate	Total	n/cN	SAR	n/adj.N	SAR
	(cN)	(n)	infection	isolation	(adj.N)				
Vaccinated	9	2	0	0	9	2/9	22%	2/9	22%
Unvaccinated	22	12	2	2	18	12/22	55%	12/18	67%
Total	31	14	2	2	27	14/31	45%	14/27	52%


264 cN: crude N, adj.N adjusted N; Adjusted SAR excludes household members infected within 6 months  
 265 prior to the infection of the staff index case and excludes household members who isolated  
 266 separately from the staff index case.

267

268

269 **Figures**

270 *Figure 1: Timeline of events and measures during a SARS-CoV-2 Alpha outbreak in a nursing home*  
271 *in Germany, Jan-Mar 2021*




272

273

274

275 *Figure 2: Cases of SARS-CoV-2 Alpha by time of diagnosis during an outbreak in a nursing home in*  
 276 *Germany, Jan-Mar 2021*

277 Color represents the area of residence or activity within the nursing home (“all” if no designation to a  
 278 specific ward). Date of diagnosis defined as the earlier date of either symptom-onset or sampling of a  
 279 positive test.



280

281



282 *Figure 3: Contact network of PCR-positive cases of a SARS-CoV-2 Alpha outbreak in a nursing home*  
 283 *in Germany, Jan-Mar 2021*

284 Star: PCR typing: Alpha


285 Asterix: PCR typing: wild type

286 Question mark: No typing performed


287 Number below symbol: ID

288 Color represents the area of residence or activity within the nursing home or external visitors or  
 289 household members

290



293 *Figure 4: Ct-Value (ORF1AB gene) of the first positive PCR by interval between second vaccination*  
294 *and diagnosis during a SARS-CoV-2 Alpha outbreak in a nursing home in Germany, Jan-Mar 2021*



295